Immunotherapies to dominate blood cancer market, with $13B revenue in 2030. FDA approves new treatment.
GT Biopharma, Inc. releases a statement regarding the recent FDA approval in November of a groundbreaking bispecific antibody combination for second-line blood cancer treatment. This approval signifies a shift away from conventional chemotherapy methods. The news was reported by USA News Group on December 19, 2025. This development marks a significant milestone in the medical field, with this innovative treatment offering new hope to patients.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments